SLC5A12 and autoimmune disease: Therefore, SLC5A12 blockade shows multidimensional beneficial effects which are reminiscent of blockade of PD1 and CTLA4 in immuno-oncology, leading us to propose that SLC5A12 represents an important example of a checkpoint in inflamed tissues in autoimmune diseases.